Although, at present, clinical trials have not found sufficient evidence for CAPE’s effects on human cancers, there was a clinical trial record (NCT02050344) which indicated that taking up to 20 mg/kg of CAPE orally only caused a minor side effect in a few participants. This evidence concerns the gene SMC2 and cancer.